Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis

References

• Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45:1558-65
   PubMed Web of Science ®Google Scholar
• Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011;13(Suppl 1):S5
   PubMed Web of Science ®Google Scholar
• Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013;11:88
   PubMed Web of Science ®Google Scholar
• Kurkó J, Besenyei T, Laki J, et al. Genetics of rheumatoid arthritis - a comprehensive review. Clin Rev Allergy Immunol 2013;45:170-9
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 2007;66:849-51
   PubMed Web of Science ®Google Scholar
• Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st century: a tool for. decisionmaking. The National Academies Press, Washington, DC USA; 1999
   Google Scholar
• Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011;127:701-21
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V, O’Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012;13:925-31
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Powrie F, Ransohoff RM. Re-establishing immunological self-tolerance in autoimmune disease. Nat Med 2012;18:54-8
   PubMed Web of Science ®Google Scholar
• Xing Y, Hogquist KA. T-Cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol 2012;4:1-15
   Google Scholar
• Pelanda R, Torres RM. Central B-cell tolerance: where selection begins. Cold Spring Harb Perspect Biol 2012;4:a007146
   PubMed Web of Science ®Google Scholar
• Sabouri Z, Schofield P, Horikawa K, et al. Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. Proc Natl Acad Sci USA 2014;111:E2567-75
   PubMed Web of Science ®Google Scholar
• Sarkar S, Cooney LA, Fox DA. The role of T helper type 17 cells in inflammatory arthritis. Clin Exp Immunol 2010;159:225-37
   PubMed Web of Science ®Google Scholar
• Notley CA, Ehrenstein MR. The yin and yang of regulatory T cells and inflammation in RA. Nat Rev Rheumatol 2010;6:572-7
   PubMedGoogle Scholar
• Wehrens EJ, Prakken BJ, van Wijk F. T cells out of control – impaired immune regulation in the inflamed joint. Nat Rev Rheumatol 2013;9:34-42
   PubMed Web of Science ®Google Scholar
• Miyara M, Ito Y, Sakaguchi S. TREG-cell therapies for autoimmune rheumatic diseases. Nat Rev Rheumatol 2014;4:1-9
   Google Scholar
• Chu Y, Wang F, Zhou M, et al. A preliminary study on the characterization of follicular helper T (Tfh) cells in rheumatoid arthritis synovium. Acta Histochem 2014;116:539-43
   PubMedGoogle Scholar
• Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis. Nat Rev Rheumatol 2014;10:593-601
   PubMed Web of Science ®Google Scholar
• Niedbala W, Wei X-Q, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007;37:3021-9
   PubMed Web of Science ®Google Scholar
• Zheng SG. Regulatory T cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive? Am J Clin Exp Immunol 2013;2:94-106
   PubMedGoogle Scholar
• Holmdahl R, Malmström V, Burkhardt H. Autoimmune priming, tissue attack and chronic inflammation - the three stages of rheumatoid arthritis. Eur J Immunol 2014;44:1593-9
   PubMed Web of Science ®Google Scholar
• Burmester GR, Feist E, Dörner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014;10:77-88
   PubMed Web of Science ®Google Scholar
• Van Herwijnen MJC, Wieten L, van der Zee R, et al. Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis. Proc Natl Acad Sci USA 2012;109:14134-9
   PubMed Web of Science ®Google Scholar
• Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010;10:849-59
   PubMed Web of Science ®Google Scholar
• Hanyecz A, Olasz K, Tarjanyi O, et al. Proteoglycan aggrecan conducting T cell activation and apoptosis in a murine model of rheumatoid arthritis. Biomed Res Int 2014;2014:942148
   PubMedGoogle Scholar
• Van de Stadt LA, de Koning MHMT, van de Stadt RJ, et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011;63:3226-33
   PubMed Web of Science ®Google Scholar
• Jardetzky TS, Lane WS, Robinson RA, et al. Identification of self peptides bound to purified HLA-B27. Nature 1991;353:326-9
   PubMed Web of Science ®Google Scholar
• Van Boekel MAM, van Venrooij WJ. Modifications of arginines and their role in autoimmunity. Autoimmun Rev 2003;2:57-62
   PubMed Web of Science ®Google Scholar
• Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-73
   PubMed Web of Science ®Google Scholar
• Bäcklund J, Treschow A, Bockermann R, et al. Glycosylation of type II collagen is of major importance for T cell tolerance and pathology in collagen-induced arthritis. Eur J Immunol 2002;32:3776-84
   PubMedGoogle Scholar
• Maresz KJ, Hellvard A, Sroka A, et al. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog 2013;9:e1003627
   PubMed Web of Science ®Google Scholar
• Shoda H, Fujio K, Shibuya M, et al. Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther 2011;13:R191
   PubMedGoogle Scholar
• Mydel P, Wang Z, Brisslert M, et al. Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol 2010;184:6882-90
   PubMed Web of Science ®Google Scholar
• Law SC, Street S, Yu C-HA, et al. T cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther 2012;14:R118
   PubMed Web of Science ®Google Scholar
• Thiele GM, Duryee MJ, Dusad A, et al. Citrullinated mouse collagen administered to DBA/1J mice in the absence of adjuvant initiates arthritis. Int Immunopharmacol 2012;13:424-31
   PubMedGoogle Scholar
• Vassallo R, Luckey D, Behrens M, et al. Cellular and humoral immunity in arthritis are profoundly influenced by the interaction between cigarette smoke effects and host HLA-DR and DQ genes. Clin Immunol 2014;152:25-35
   PubMed Web of Science ®Google Scholar
• Von Delwig A, Locke J, Robinson JH, et al. Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum 2010;62:143-9
   PubMed Web of Science ®Google Scholar
• Wegner N, Lundberg K, Kinloch A, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010;233:34-54
   PubMed Web of Science ®Google Scholar
• Burkhardt H, Holmdahl R, Deutzmann R, et al. Identification of a major antigenic epitope on CNBr-fragment 11 of type II collagen recognized by murine autoreactive B cells. Eur J Immunol 1991;21:49-54
   PubMed Web of Science ®Google Scholar
• Terato K, Hasty KA, Cremer MA, et al. Collagen-induced arthritis in mice. Localization of an arthritogenic determinant to a fragment of the type II collagen molecule. J Exp Med 1985;162:637-46
   PubMed Web of Science ®Google Scholar
• Glant T, Csongor J, Szücs T. Immunopathologic role of proteoglycan antigens in rheumatoid joint disease. Scand J Immunol 1980;11:247-52
   PubMed Web of Science ®Google Scholar
• Von Delwig A, Altmann DM, Charlton FG, et al. T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice. Ann Rheum Dis 2007;66:599-604
   PubMed Web of Science ®Google Scholar
• Glant TT, Buzás EI, Finnegan A, et al. Critical roles of glycosaminoglycan side chains of cartilage proteoglycan (aggrecan) in antigen recognition and presentation. J Immunol 1998;160:3812-19
   PubMedGoogle Scholar
• Misják P, Bősze S, Horváti K, et al. The role of citrullination of an immunodominant proteoglycan (PG) aggrecan T cell epitope in BALB/c mice with PG-induced arthritis. Immunol Lett 2013;152:25-31
   PubMedGoogle Scholar
• Kinne RW. (Auto)immunity to cartilage matrix proteins - a time bomb? Arthritis Res Ther 2013;15:101
   PubMedGoogle Scholar
• Kobezda T, Ghassemi-Nejad S, Mikecz K, et al. Of mice and men: how animal models advance our understanding of T-cell function in RA. Nat Rev Rheumatol 2014;10:160-70
   PubMed Web of Science ®Google Scholar
• Strzępa A, Szczepanik M. IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders. Pharmacol Rep 2011;63:30-44
   PubMedGoogle Scholar
• Van den Berg WB. Lessons from animal models of arthritis over the past decade. Arthritis Res Ther 2009;11:250
   PubMedGoogle Scholar
• Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81
   PubMed Web of Science ®Google Scholar
• Hu Y, Cheng W, Cai W, et al. Advances in research on animal models of rheumatoid arthritis. Clin Rheumatol 2013;32:161-5
   PubMed Web of Science ®Google Scholar
• Andersson M, Holmdahl R. Analysis of type II collagen-reactive T cells in the mouse. I. Different regulation of autoreactive vs. non-autoreactive anti-type II collagen T cells in the DBA/1 mouse. Eur J Immunol 1990;20:1061-6
   PubMed Web of Science ®Google Scholar
• Backlund J, Li C, Jansson E, et al. C57BL/6 mice need MHC class II Aq to develop collagen-induced arthritis dependent on autoreactive T cells. Ann Rheum Dis 2013;72(7):1225-32
   PubMedGoogle Scholar
• Campbell IK, Hamilton JA, Wicks IP. Collagen-induced arthritis in C57BL/6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis. Eur J Immunol 2000;30:1568-75
   PubMedGoogle Scholar
• Lindh I, Snir O, Lönnblom E, et al. Type II collagen antibody response is enriched in the synovial fluid of rheumatoid joints and directed to the same major epitopes as in collagen induced arthritis in primates and mice. Arthritis Res Ther 2014;16:R143
   PubMedGoogle Scholar
• Glant TT, Mikecz K, Arzoumanian A, et al. Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology. Arthritis Rheum 1987;30:201-12
   PubMed Web of Science ®Google Scholar
• Mikecz K, Glant TT, Poole AR. Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglycan. Arthritis Rheum 1987;30:306-18
   PubMed Web of Science ®Google Scholar
• Glant TT, Radacs M, Nagyeri G, et al. Proteoglycan-induced arthritis and recombinant human proteoglycan aggrecan G1 domain-induced arthritis in BALB/c mice resembling two subtypes of rheumatoid arthritis. Arthritis Rheum 2011;63:1312-21
   PubMedGoogle Scholar
• Glant TT, Finnegan A, Mikecz K. Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics. Crit Rev Immunol 2003;23:199-250
   PubMed Web of Science ®Google Scholar
• Deane KD. Can rheumatoid arthritis be prevented? Best Pract Res Clin Rheumatol 2013;27:467-85
   PubMed Web of Science ®Google Scholar
• Farkas B, Boldizsar F, Tarjanyi O, et al. BALB/c mice genetically susceptible to proteoglycan-induced arthritis and spondylitis show colony-dependent differences in disease penetrance. Arthritis Res Ther 2009;11:R21
   PubMedGoogle Scholar
• Maggi L, Santarlasci V, Capone M, et al. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. Eur J Immunol 2012;42:3180-8
   PubMed Web of Science ®Google Scholar
• Rodeghero R, Cao Y, Olalekan SA, et al. Location of CD4+ T cell priming regulates the differentiation of Th1 and Th17 cells and their contribution to arthritis. J Immunol 2013;190:5423-35
   PubMedGoogle Scholar
• Domingues HS, Mues M, Lassmann H, et al. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS One 2010;5:e15531
   PubMed Web of Science ®Google Scholar
• Luger D, Silver PB, Tang J, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008;205:799-810
   PubMed Web of Science ®Google Scholar
• Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 2014;73:3-5
   PubMed Web of Science ®Google Scholar
• Mócsai A, Kovács L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med 2014;12:43
   PubMed Web of Science ®Google Scholar
• Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 2013;15(Suppl 3):S2
   PubMed Web of Science ®Google Scholar
• Colmegna I, Ohata BR, Menard HA. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther 2012;91:607-20
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus Methotrexate in Rheumatoid Arthritis. N Engl J Med 2014;370:2377-86
   PubMed Web of Science ®Google Scholar
• Ferraro B, Morrow MP, Hutnick NA, et al. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011;53:296-302
   PubMed Web of Science ®Google Scholar
• Kallen K-J, Theß A. A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines 2014;2:10-31
   PubMedGoogle Scholar
• Wu T-C, Xu K, Banchereau R, et al. Reprogramming tumor-infiltrating dendritic cells for CD103+CD8+ mucosal T-cell differentiation and breast cancer rejection. Cancer Immunol Res 2014;2:487-500
   PubMedGoogle Scholar
• Snook AE, Magee MS, Schulz S, et al. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol 2014;44:1956-66
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Sagiv-Barfi I, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013;123:2447-63
   PubMed Web of Science ®Google Scholar
• Bäckström NF, Dahlgren UIH. Bystander suppression of collagen-induced arthritis in mice fed ovalbumin. Arthritis Res Ther 2004;6:R151-60
   PubMedGoogle Scholar
• Oki S, Tomi C, Yamamura T, et al. Preferential T(h)2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo. Int Immunol 2005;17:1619-29
   PubMedGoogle Scholar
• Lu S, Holmdahl R. Different therapeutic and bystander effects by intranasal administration of homologous type II and type IX collagens on the collagen-induced arthritis and pristane-induced arthritis in rats. Clin Immunol 1999;90:119-27
   PubMed Web of Science ®Google Scholar
• Perez SA, von Hofe E, Kallinteris NL, et al. A new era in anticancer peptide vaccines. Cancer 2010;116:2071-80
   PubMed Web of Science ®Google Scholar
• Tovey MG, Lallemand C. Adjuvant activity of cytokines. Methods Mol Biol 2010;626:287-309
   PubMedGoogle Scholar
• Assier E, Semerano L, Duvallet E, et al. Modulation of anti-tumor necrosis factor alpha (TNF-α) antibody secretion in mice immunized with TNF-α kinoid. Clin Vaccine Immunol 2012;19:699-703
   PubMedGoogle Scholar
• Hasselberg A, Schön K, Tarkowski A, et al. Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis. Arthritis Rheum 2009;60:1672-82
   PubMedGoogle Scholar
• Dzhambazov B, Nandakumar KS, Kihlberg J, et al. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J Immunol 2006;176:1525-33
   PubMed Web of Science ®Google Scholar
• Boonnak K, Vogel L, Orandle M, et al. Antigen-activated dendritic cells ameliorate influenza A infections. J Clin Invest 2013;123:2850-61
   PubMedGoogle Scholar
• Pleguezuelos O, Robinson S, Stoloff GA, et al. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine 2012;30:4655-60
   PubMed Web of Science ®Google Scholar
• Melief CJM. Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine. J Immunother 2012;35:215-16
   PubMed Web of Science ®Google Scholar
• Quakkelaar ED, Melief CJM. Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv Immunol 2012;114:77-106
   PubMed Web of Science ®Google Scholar
• Zeestraten ECM, Speetjens FM, Welters MJP, et al. Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer 2013;132:1581-91
   PubMed Web of Science ®Google Scholar
• Feng GD, Xue XC, Gao ML, et al. Therapeutic effects of PADRE-BAFF autovaccine on rat adjuvant arthritis. Biomed Res Int 2014;2014:854954
   PubMed Web of Science ®Google Scholar
• Baleeiro RB, Wiesmüller K-H, Dähne L, et al. Direct activation of human dendritic cells by particle-bound but not soluble MHC class II ligand. PLoS One 2013;8:e63039
   PubMedGoogle Scholar
• Xu M, Capraro GA, Daibata M, et al. Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. Mol Immunol 1994;31:723-31
   PubMed Web of Science ®Google Scholar
• Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 2010;185:5677-82
   PubMed Web of Science ®Google Scholar
• Mitchell D, Yong M, Raju J, et al. Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: implications for peptide vaccines. Hum Vaccin 2011;7(Suppl):85-93
   PubMedGoogle Scholar
• Kim S-J, Chen Z, Chamberlain ND, et al. Ligation of TLR5 promotes myeloid cell infiltration and differentiation into mature osteoclasts in rheumatoid arthritis and experimental arthritis. J Immunol 2014;193:3902-13
   PubMedGoogle Scholar
• Rosenthal KS, Taylor P, Zimmerman DH. J-LEAPS peptide and LEAPS dendritic cell vaccines. Microb Biotechnol 2012;5:203-13
   PubMedGoogle Scholar
• Zimmerman DH. LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases. J Vaccines Vaccin 2012;03:1000149
   Google Scholar
• Ohnishi Y, Tsutsumi A, Matsumoto I, et al. Altered peptide ligands control type II collagen-reactive T cells from rheumatoid arthritis patients. Mod Rheumatol 2006;16:226-8
   PubMedGoogle Scholar
• Wakamatsu E, Matsumoto I, Yoshiga Y, et al. Altered peptide ligands regulate type II collagen-induced arthritis in mice. Mod Rheumatol 2009;19:366-71
   PubMed Web of Science ®Google Scholar
• Doodes PD, Cao Y, Hamel KM, et al. IFN-gamma regulates the requirement for IL-17 in proteoglycan-induced arthritis. J Immunol 2010;184:1552-9
   PubMedGoogle Scholar
• Alzabin S, Abraham SM, Taher TE, et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis 2012;71:1741-8
   PubMed Web of Science ®Google Scholar
• Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 2001;108:415-23
   PubMed Web of Science ®Google Scholar
• Kochetkova I, Trunkle T, Callis G, et al. Vaccination without autoantigen protects against collagen II-induced arthritis via immune deviation and regulatory T cells. J Immunol 2008;181:2741-52
   PubMedGoogle Scholar
• Luross JA, Heaton T, Hirst TR, et al. Escherichia coli heat-labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells. Arthritis Rheum 2002;46:1671-82
   PubMedGoogle Scholar
• Zimmerman DH, Taylor P, Bendele A, et al. CEL-2000: a therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. Int Immunopharmacol 2010;10:412-21
   PubMedGoogle Scholar
• Sidhu M, Griffiths MM, Bradley DS. Vaccination with collagen-pulsed dendritic cells prevents the onset and reduces the disease severity in the mouse model of spontaneous polychondritis. Clin Exp Immunol 2009;157:350-8
   PubMed Web of Science ®Google Scholar
• Zimmerman D, Mikecz K, Kurko J, et al. LEAPS peptide vaccination alters T cell phenotype and suppresses joint inflammation in a murine model of rheumatoid arthitis (P5223). J Immunol 2013;190:67.6
   Google Scholar
• Prakken BJ, Roord S, Ronaghy A, et al. Heat shock protein 60 and adjuvant arthritis: a model for T cell regulation in human arthritis. Springer Semin Immunopathol 2003;25:47-63
   PubMed Web of Science ®Google Scholar
• Koffeman EC, Genovese M, Amox D, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II tria. Arthritis Rheum 2009;60:3207-16
   PubMed Web of Science ®Google Scholar
• Cammarota G, Scheirle A, Takacs B, et al. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature 1992;356:799-801
   PubMed Web of Science ®Google Scholar
• König R, Huang LY, Germain RNN. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature 1992;356:796-8
   PubMed Web of Science ®Google Scholar
• Taylor PR, Paustian CC, Koski GK, et al. Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens. Cell Immunol 2010;262:1-5
   PubMedGoogle Scholar
• Taylor PR, Koski GK, Paustian CC, et al. J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. Vaccine 2010;28:5533-42
   PubMedGoogle Scholar
• Zimmerman DH, Morris S, Rouse D, et al. Immunization with peptide heterconjugates primes a t helper cell type 1-associated antibody (IgG2a) response that recognizes the native epitope on the 38-kDA protein of Mycobacterium tuberculosis. Vaccine Res Liebert 1996;5:103-18
   Google Scholar
• Goel N, Zimmerman DH, Rosenthal KS. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Front Biosci 2005;10:966-74
   PubMed Web of Science ®Google Scholar
• König R, Shen X, Germain RN. Involvement of both major histocompatibility complex class II alpha and beta chains in CD4 function indicates a role for ordered oligomerization in T cell activation. J Exp Med 1995;182:779-87
   PubMedGoogle Scholar
• Rosenthal KS, Mao H, Horne WI, et al. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine 1999;17:535-42
   PubMed Web of Science ®Google Scholar
• Goel N, Rong Q, Zimmerman D, et al. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Vaccine 2003;21:4410-20
   PubMed Web of Science ®Google Scholar
• Zimmerman D, Bergmann K, Rosenthal K, et al. A new approach to T-cell activation: natural and synthetic conjugates capable of activating T cells. Vaccine Res 1996;5:91-102
   Google Scholar
• Cihakova D, Barin JG, Baldeviano GC, et al. L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart. Int Immunopharmacol 2008;8:624-33
   PubMedGoogle Scholar
• Finnegan A, Mikecz K, Tao P, et al. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol 1999;163:5383-90
   PubMedGoogle Scholar
• Cao Y, Brombacher F, Tunyogi-Csapo M, et al. Interleukin-4 regulates proteoglycan-induced arthritis by specifically suppressing the innate immune response. Arthritis Rheum 2007;56:861-70
   PubMedGoogle Scholar
• Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 2014;13:419-31
   PubMed Web of Science ®Google Scholar
• Bendele A. Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact 2001;1:377-85
   PubMedGoogle Scholar
• Bevaart L, Vervoordeldonk MJ, Tak PP. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum 2010;62:2192-205
   PubMedGoogle Scholar
• Billiau A, Matthys P. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001;70:849-60
   PubMed Web of Science ®Google Scholar
• Schurgers E, Billiau A, Matthys P. Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-γ. J Interferon Cytokine Res 2011;31:917-26
   PubMed Web of Science ®Google Scholar
• Boissier MC, Chiocchia G, Bessis N, et al. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol 1995;25:1184-90
   PubMed Web of Science ®Google Scholar
• Bolon B, Stolina M, King C, et al. Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J Biomed Biotechnol 2011;2011:569068
   PubMedGoogle Scholar
• Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc 2007;2:1269-75
   PubMed Web of Science ®Google Scholar
• Brand DD. Rodent models of rheumatoid arthritis. Comp Med 2005;55:114-22
   PubMed Web of Science ®Google Scholar
• Chu C-Q, Swart D, Alcorn D, et al. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 2007;56:1145-51
   PubMedGoogle Scholar
• Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 2005;12:167-81
   PubMedGoogle Scholar
• Lindqvist A-KB, Bockermann R, Johansson ÅC, et al. Mouse models for rheumatoid arthritis. Trends Genet 2002;18:S7-S13
   Google Scholar
• Malfait AM, Butler DM, Presky DH, et al. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol 1998;111:377-83
   PubMed Web of Science ®Google Scholar
• Glant TT, Mikecz K. Proteoglycan aggrecan-induced arthritis: a murine autoimmune model of rheumatoid arthritis. Methods Mol Med 2004;102:313-38
   PubMedGoogle Scholar
• Nandakumar KS, Holmdahl R. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther 2006;8:223
   PubMedGoogle Scholar
• Nandakumar KS, Holmdahl R. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods 2005;304:126-36
   PubMedGoogle Scholar
• Patten C, Bush K, Rioja I, et al. Characterization of pristane-induced arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunopathology. Arthritis Rheum 2004;50:3334-45
   PubMedGoogle Scholar
• Vingsbo C, Sahlstrand P, Brun JG, et al. Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am J Pathol 1996;149:1675-83
   PubMed Web of Science ®Google Scholar
• Cromartie WJJ. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med 1977;146:1585-602
   PubMed Web of Science ®Google Scholar
• Joosten LA, Helsen MM, van Den Berg WB. Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and interleukin 1Ra. Ann Rheum Dis 2000;59:196-205
   PubMed Web of Science ®Google Scholar
• Plater-Zyberk C, Joosten LAB, Helsen MMA, et al. GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis 2007;66:452-7
   PubMed Web of Science ®Google Scholar
• Holmdahl R, Lorentzen JCC, Lu S, et al. Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis. Immunol Rev 2001;184:184-202
   PubMed Web of Science ®Google Scholar
• Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 2011;33:679-707
   PubMed Web of Science ®Google Scholar
• Bajtner E, Nandakumar KS, Engström A, et al. Chronic development of collagen-induced arthritis is associated with arthritogenic antibodies against specific epitopes on type II collagen. Arthritis Res Ther 2005;7:R1148-57
   PubMedGoogle Scholar
• Mould AW, Scotney P, Greco SA, et al. Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGF-B to VEGFR-1 in a murine collagen-induced arthritis model. Rheumatology (Oxford) 2008;47:263-6
   PubMedGoogle Scholar
• Hamel K, Doodes P, Cao Y, et al. Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J Immunol 2008;180:4994-5003
   PubMedGoogle Scholar
• Prakken BJ, Samodal R, Le TD, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA 2004;101:4228-33
   PubMed Web of Science ®Google Scholar
• Iizuka M, Wakasa Y, Tsuboi H, et al. Suppression of collagen-induced arthritis by oral administration of transgenic rice seeds expressing altered peptide ligands of type II collagen. Plant Biotechnol J 2014;12:1143-52
   PubMed Web of Science ®Google Scholar
• Orgogozo J-M, Gilman S, Dartigues J-F, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54
   PubMed Web of Science ®Google Scholar
• Kappos L, Comi G, Panitch H, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000;6:1176-82
   PubMed Web of Science ®Google Scholar
• McDevitt H. Specific antigen vaccination to treat autoimmune disease. Proc Natl Acad Sci USA 2004;101(Suppl 2):14627-30
   PubMedGoogle Scholar
• Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007;120:506-15. quiz 516–7
   PubMed Web of Science ®Google Scholar
• Pedotti R, DeVoss JJ, Youssef S, et al. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Natl Acad Sci USA 2003;100:1867-72
   PubMed Web of Science ®Google Scholar
• Pedotti R, Sanna M, Tsai M, et al. Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. BMC Immunol 2003;4:2
   PubMedGoogle Scholar
• Kobayashi M, Abiru N, Arakawa T, et al. Altered B:9-23 insulin, when administered intranasally with cholera toxin adjuvant, suppresses the expression of insulin autoantibodies and prevents diabetes. J Immunol 2007;179:2082-8
   PubMedGoogle Scholar
• Mitamura M, Nakano N, Yonekawa T, et al. T cells are involved in the development of arthritis induced by anti-type II collagen antibody. Int Immunopharmacol 2007;7:1360-8
   PubMedGoogle Scholar
• Kobayashi N, Kiptoo P, Kobayashi H, et al. Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. Clin Immunol 2008;129:69-79
   PubMedGoogle Scholar
• Liu E, Moriyama H, Abiru N, et al. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest 2002;110:1021-7
   PubMed Web of Science ®Google Scholar
• Liu E, Moriyama H, Paronen J, et al. Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulin autoantibodies following insulin peptide B:9-23 immunization in the NOD mouse. J Autoimmun 2003;21:213-19
   PubMed Web of Science ®Google Scholar
• Liu E, Moriyama H, Abiru N, et al. Preventing peptide-induced anaphylaxis: addition of C-terminal amino acids to produce a neutral isoelectric point. J Allergy Clin Immunol 2004;114:607-13
   PubMedGoogle Scholar
• Quakkelaar ED, Fransen MF, van Maren WWC, et al. IgG-mediated anaphylaxis to a synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation. J Immunol 2014;192:5813-20
   PubMed Web of Science ®Google Scholar